Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Annette S. Little(Babraham Institute), Simon J. Cook(Babraham Institute), Paul D. Smith(Epworth Hospital), Scott Newman(Guardant (United States)), Kathryn Balmanno(Babraham Institute), Mark Hampson, Paul A. Edwards(University of Cambridge), Jonathan R. Dry(AstraZeneca (United Kingdom)), Matthew J. Sale(University of California, San Francisco)
Cited by 209
Related Papers
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing
|Nature Genetics|2008|841
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627